ArticleEuropean journal of nuclear medicine and molecular imaging2026
Deep integration of clinical metadata with [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeTo develop and validate a multimodal deep learning framework that integrates clinical metadata with [
methodsA multi-center surgical NSCLC cohort (n = 780) was partitioned into a development set (n = 675) and an independent external test set (n = 105). The framework first utilized a 3D Transformer for bounding-box-based tumor localization. Subsequently, a multi-task network employed Feature-wise Linear Modulation (FiLM) to dynamically inject clinical metadata into the visual backbone.
resultsFor histological subtyping of adenocarcinoma versus squamous cell carcinoma, in the validation cohort, the proposed multimodal framework achieved the highest area under the receiver operating characteristic curve (AUC) of 0.894 (95% CI: 0.813-0.959), significantly outperforming the conventional radiomics baseline (AUC = 0.796, DeLong test P = 0.017) and the clinical-only baseline (AUC = 0.759, P = 0.004). On the internal test set, the multimodal model maintained an AUC of 0.832 (95% CI: 0.744-0.906), outperforming competing models numerically, though differences did not reach statistical significance (all P > 0.11). On the independent external test cohort, the multimodal framework demonstrated superior cross-center stability, maintaining an AUC of 0.787 (95% CI: 0.687-0.876). On the external cohort, the between-model AUC differences did not reach statistical significance against the clinical-only model (AUC of 0.740, P = 0.480) or the image-only model (AUC of 0.685, P = 0.082). Nevertheless, the multimodal framework achieved the highest F1-score and yielded the most optimal net clinical benefit across a wide range of threshold probabilities in decision curve analysis. For the intrinsically challenging auxiliary staging task, the unguided image-only network exhibited severe vulnerability, however, the FiLM-based multimodal mechanism effectively enhanced diagnostic capacity by employing systemic clinical priors, improving the AUC to 0.656.
conclusionCombining 3D detection with an early clinico-biological fusion strategy effectively enhances NSCLC characterization on [
Indexed as
Identifiers
42310216What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.